DoriVac: A Stable DNA Origami Vaccine Platform Beyond mRNA

A new DNA origami vaccines platform known as DoriVac may offer a strong alternative to current mRNA vaccines. Early laboratory studies suggest that this platform can produce a powerful immune response while being more stable, easier to manufacture, and potentially more practical for large-scale vaccine production.

The COVID-19 pandemic brought messenger RNA vaccines into worldwide attention. After successful clinical trials, the first COVID-19 mRNA vaccine was administered on December 8, 2020. Later scientific modeling suggested that these vaccines helped prevent at least 14.4 million deaths globally during their first year of use.

Because of this success, researchers began exploring mRNA vaccine technology for other major infectious diseases. Current vaccine research and clinical studies are focused on illnesses such as influenza, Respiratory Syncytial Virus (RSV), HIV, Zika virus, Epstein-Barr virus, and tuberculosis.

However, research on COVID-19 vaccines has also shown some important challenges. These include issues related to vaccine stability, storage conditions, production complexity, and long-term protection. These limitations have encouraged scientists to develop new next-generation vaccine platforms like DoriVac, which may help improve future immunization strategies.

Key Limits of mRNA Vaccines and Their Manufacturing Process

COVID-19 mRNA vaccines have played an important role in controlling the pandemic, but their immune protection can vary from one person to another. For some people, the protection may be strong, while for others it may be weaker or decrease over time. This means that vaccine-induced immunity does not always last permanently.

Another major challenge is the continuous evolution of SARS-CoV-2. As the virus changes, new variants can appear with the ability to partly escape the body’s immune defenses. Because of this, mRNA vaccine formulations often need to be updated to match newer viral strains.

There are also serious production and storage issues. The manufacturing process for mRNA vaccines is costly, highly technical, and difficult to scale. It is also challenging to control the exact number of mRNA molecules packed inside lipid nanoparticles, which are used to deliver the vaccine into cells.

In addition, many mRNA-based vaccines require cold-chain storage, making global distribution harder, especially in regions with limited medical infrastructure. Some studies have also raised concerns about possible off-target effects, where the vaccine may affect areas beyond its intended biological target.

Solving these problems could support the development of safer, more stable, and more accessible next-generation vaccine platforms. This would help improve global readiness against future infectious disease outbreaks, emerging viral variants, and pandemic-level health threats.

DoriVac DNA Origami Vaccine Shows Promise as a New Vaccine Strategy

A DNA origami vaccine platform called DoriVac may provide a new way to overcome some of the main problems linked with mRNA vaccines. This approach was studied by a multidisciplinary research team from the Wyss Institute at Harvard University, the Dana-Farber Cancer Institute, and other partner organizations.

DoriVac is based on DNA origami nanotechnology. It is designed to work both as a vaccine platform and as an adjuvant, meaning it can help the body recognize a target and strengthen the immune response at the same time.

The researchers created DoriVac vaccines that target a peptide region called HR2, which is found in the spike proteins of several viruses, including SARS-CoV-2, HIV, and Ebola virus. In mouse studies, the SARS-CoV-2 HR2 vaccine produced strong humoral immune responses, driven by antibodies, as well as strong cellular immune responses, driven by T cells.

The team also tested the vaccine using a preclinical human model. For this, they used the Wyss Institute’s microfluidic human Organ Chip technology, which can recreate some functions of a human lymph node in the laboratory. In this human-cell-based system, the SARS-CoV-2 HR2 DoriVac vaccine also triggered strong antigen-specific immune activity.

The researchers then compared DoriVac with SARS-CoV-2 mRNA vaccines delivered through lipid nanoparticles. When both platforms carried the same spike protein variant, the DNA origami vaccine produced a similar level of immune activation in human models.

However, DoriVac showed important practical advantages. It appeared to be more stable, easier to store, and simpler to manufacture than traditional mRNA vaccine platforms. These findings suggest that DNA origami vaccines could become a useful part of future next-generation vaccine development, especially for preparing against emerging infectious diseases and new viral threats.

DoriVac Gives Scientists Precise Control Over Immune Response

Professor William Shih, Ph.D., co-corresponding author of the study and Core Faculty member at the Wyss Institute, said the DoriVac platform provides a highly flexible vaccine structure with several important advantages.

According to Shih, DoriVac allows researchers to control the exact vaccine composition with unusual precision. It also gives scientists the ability to guide immune recognition in specific immune cells at the molecular level, which may help produce stronger and more targeted immune responses.

The study shows that DoriVac is a versatile DNA origami vaccine platform with strong potential for future infectious disease vaccines. By studying the immune changes needed to fight harmful viruses, the research highlights how this technology could support the development of more effective next-generation vaccines.

Shih’s research group helped pioneer this new vaccine concept. He also serves as a professor at Harvard Medical School and the Dana-Farber Cancer Institute.

How DoriVac DNA Origami Vaccines Are Designed

The DoriVac vaccine platform was first introduced in 2024 by Professor William Shih’s team at the Wyss Institute at Harvard University and the Dana-Farber Cancer Institute. The platform is based on DNA nanotechnology and was developed as a flexible system for different vaccine applications.

The work was led by Yang “Claire” Zeng, M.D., Ph.D., together with several collaborators. Their research showed that DoriVac can place immune-stimulating adjuvant molecules on cells with very high precision at the nanoscale level.

Earlier studies in tumor-bearing mice showed that vaccines using the DNA origami structure created stronger immune responses than similar vaccines without this structure. This suggests that the shape and design of the vaccine can strongly affect how the body reacts to it.

DoriVac vaccines are made from very small, self-assembling square DNA nanostructures. One side carries carefully arranged adjuvant molecules, placed at controlled nanometer distances. The other side displays selected antigens, such as peptides or proteins taken from tumors, viruses, or other pathogens.

While the platform was being developed for cancer vaccines, the COVID-19 pandemic was still a major global health crisis. This raised an important question: could DoriVac’s strong adjuvant activity also be used to fight infectious diseases?

To answer this, Zeng and Olivia Young, Ph.D., a former graduate student in Shih’s group, worked with Donald Ingber’s team at the Wyss Institute. Ingber’s group studies antiviral technologies using AI-driven research, multiomics analysis, and microfluidic human Organ Chip systems.

Together with Longlong Si, Ph.D., a former postdoctoral researcher in Ingber’s lab, the team created DoriVac vaccines designed to target SARS-CoV-2, HIV, and Ebola virus. These vaccines display HR2 peptides, which are conserved viral antigens found in spike proteins. Because these regions are shared across different viruses, they may help support broader and more reliable immune protection.

DoriVac Triggers Stronger Long-Term Immune Protection

Early testing of the first DoriVac vaccines in mice showed promising results. According to Yang “Claire” Zeng, the vaccines produced stronger and wider immune activation than separate antigens and adjuvants used without the DNA origami structure.

The results showed improved activity in both major parts of the immune system. This included humoral immunity, which depends mainly on antibodies, and cellular immunity, which involves protective T cells.

Researchers found higher numbers of antibody-producing B cells, activated dendritic cells, and antigen-specific T cells. These immune cells are important because they help the body recognize harmful viruses, attack infected cells, and build long-term immune memory.

The strongest response was seen with the SARS-CoV-2 HR2 DoriVac vaccine. It increased important memory T cells and cytotoxic T cells, which play a key role in lasting protection against future viral infection.

Overall, these findings suggest that the DNA origami vaccine platform may help create stronger, broader, and longer-lasting immune responses than traditional antigen-adjuvant combinations.

Read Also: Ape Laughter Hints at Human Speech [Hidden Origin]

Testing DoriVac in Human Immune System Models

A major problem in vaccine development is that results from mouse studies do not always match what happens in humans. Many treatments that look successful in animals later fail during clinical trials because the human immune system responds differently.

To reduce this gap, the researchers tested DoriVac vaccines in a human lymph node-on-a-chip, also called a human LN Chip. This advanced microfluidic Organ Chip model is designed to copy important parts of the human immune response in the laboratory.

The system was developed further by Min Wen Ku and Girija Goyal, Ph.D., Director of Bioinspired Therapeutics at the Wyss Institute. Using this model, the team found that the SARS-CoV-2 HR2 DoriVac vaccine strongly activated human dendritic cells, also known as DCs. These cells are important because they help the immune system recognize harmful antigens and start a protective response.

Compared with vaccine components that did not use the DNA origami structure, the DoriVac vaccine caused human DCs to release much higher levels of inflammatory cytokines. These signaling molecules help coordinate immune activation against infection.

The vaccine also increased the number of CD4+ T cells and CD8+ T cells with several protective functions. These T cell responses are important for recognizing infected cells, supporting antibody production, and building stronger long-term immunity.

According to Donald Ingber, M.D., Ph.D., the human LN Chip provided a powerful testing system because it can better predict how human immune cells may respond to a vaccine. He explained that combining DNA origami vaccine technology with human Organ Chip models could improve the chances of success for this new class of vaccines.

Overall, these findings suggest that DoriVac may have real potential for future human vaccine development, especially against infectious diseases, viral variants, and other emerging health threats.

DoriVac Shows Similar Immune Power With Easier Vaccine Delivery

Researchers also tested a DoriVac vaccine that displays the full SARS-CoV-2 spike protein. This part of the study was led by Yang “Claire” Zeng and co-author Qiancheng Xiong.

The team compared this DNA origami vaccine with Moderna and Pfizer-BioNTech mRNA vaccines, which use lipid nanoparticles, also known as LNPs, to deliver instructions for the same spike protein.

In mouse studies using a standard booster vaccination method, both vaccine types produced similar levels of antiviral T cell responses and antibody-producing B cell responses. This showed that DoriVac may activate the immune system as strongly as leading mRNA-LNP vaccine platforms.

However, DoriVac may offer some practical advantages. Unlike many mRNA vaccines, it does not appear to need the same strict cold-chain storage conditions. This could make vaccine transport and delivery easier, especially in under-resourced regions where advanced refrigeration systems are limited.

The platform may also reduce some of the major manufacturing challenges linked with LNP-formulated vaccines. Because DoriVac is based on DNA nanotechnology and works as a self-adjuvanted vaccine platform, it may be easier to design, produce, store, and distribute at scale.

Recent work from DoriNano also suggests that DoriVac has a promising safety profile, supporting its potential for future clinical vaccine development.

The study involved researchers from several institutions and was supported by the Wyss Institute, the Dana-Farber Cancer Institute, the National Institutes of Health, the US-Japan CRDF Global Fund, the National Research Foundation of Korea, the Korea Institute of Science and Technology, and the Bill & Melinda Gates Foundation.

Overall, these results suggest that DoriVac DNA origami vaccines could become a strong next-generation vaccine platform, combining powerful immune activation with better stability, simpler storage, and more practical global distribution.

Summary: DNA Origami Vaccines May Beat mRNA [Next Leap]

DoriVac is a new DNA origami vaccine platform that may become a strong alternative to mRNA vaccines.Early studies show it can trigger powerful antibody, T cell, and long-term immune responses.It may be more stable, easier to store, and simpler to manufacture than mRNA-LNP vaccines.Researchers tested it in mice and human lymph node-on-a-chip models, where it showed strong immune activation.These results suggest DoriVac could support future vaccines against SARS-CoV-2, HIV, Ebola, and other infectious diseases.